Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.
Lei LiuZhen RuanCarolina Oi Lam UngYawen ZhangYang ShenSheng HanRuxu JiaJingtao QiaoHao HuLixin GuoPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
From the perspective of Chinese healthcare systems, treatment with once-weekly subcutaneous semaglutide represents a dominant option versus PEG-loxenatide for patients with type 2 diabetes uncontrolled on metformin.